Home
IMNM
IMNM News

Latest Immunome Inc. (IMNM) News on February 22, 2025

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

16 days ago

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Insider Stock Buying Reaches US$2.82m On Immunome

Simply Wall St.

18 days ago

Insider Stock Buying Reaches US$2.82m On Immunome

MT Newswires

22 days ago

Immunome Closes Public Offering of Shares

Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Business Wire

22 days ago

Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

MT Newswires

24 days ago

Immunome Prices $150 Million Stock Offering

Immunome Announces Pricing of Upsized Public Offering of Common Stock

Business Wire

24 days ago

Immunome Announces Pricing of Upsized Public Offering of Common Stock

Immunome Announces Proposed Public Offering of Common Stock

Business Wire

24 days ago

Immunome Announces Proposed Public Offering of Common Stock

Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Business Wire

a month ago

Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

MT Newswires

a month ago

Immunome Obtains Worldwide License to Hummingbird's Monoclonal Antibodies

Hummingbird Bioscience Licenses Novel Antibodies to Immunome

GlobeNewswire

a month ago

Hummingbird Bioscience Licenses Novel Antibodies to Immunome

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

2 months ago

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

3 months ago

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference

Business Wire

3 months ago

Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference

Argus Research

3 months ago

Daily – Vickers Top Buyers & Sellers for 11/26/2024

MT Newswires

3 months ago

Immunome Insider Bought Shares Worth $962,181, According to a Recent SEC Filing

MT Newswires

3 months ago

Immunome Files Prospectus for Stock Offering By Selling Shareholders

Immunome Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

3 months ago

Immunome Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Immunome, Inc. (IMNM) Reports Q3 Loss, Misses Revenue Estimates

Zacks

3 months ago

Immunome, Inc. (IMNM) Reports Q3 Loss, Misses Revenue Estimates

Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update

Business Wire

3 months ago

Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update

ImmunityBio (IBRX) Reports Q3 Loss, Tops Revenue Estimates

Zacks

3 months ago

ImmunityBio (IBRX) Reports Q3 Loss, Tops Revenue Estimates

MT Newswires

3 months ago

Stephens Starts Immunome With Overweight Rating, $30 Price Target

Immunome to Present at Guggenheim’s Inaugural Healthcare Innovation Conference

Business Wire

4 months ago

Immunome to Present at Guggenheim’s Inaugural Healthcare Innovation Conference

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

4 months ago

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome Advances with Strategic Asset Acquisition and Agreement

TipRanks

4 months ago

Immunome Advances with Strategic Asset Acquisition and Agreement

Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021

Business Wire

4 months ago

Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021

Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium

Business Wire

4 months ago

Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium

Immunome Appoints Roee Shahar as Executive Vice President, Commercial

Business Wire

4 months ago

Immunome Appoints Roee Shahar as Executive Vice President, Commercial

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

4 months ago

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

Business Wire

5 months ago

Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Business Wire

6 months ago

Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Immunome Stock Sees RS Rating Jump To 91

Investor's Business Daily

6 months ago

Immunome Stock Sees RS Rating Jump To 91

Immunome Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

6 months ago

Immunome Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Immunome, Inc. (IMNM) Reports Q2 Loss, Misses Revenue Estimates

Zacks

6 months ago

Immunome, Inc. (IMNM) Reports Q2 Loss, Misses Revenue Estimates

MT Newswires

6 months ago

Immunome Q2 Net Loss Widens, Revenue Drops

Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update

Business Wire

6 months ago

Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update

Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities

Business Wire

7 months ago

Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities

Immunome Insiders Added US$2.67m Of Stock To Their Holdings

Simply Wall St.

7 months ago

Immunome Insiders Added US$2.67m Of Stock To Their Holdings

Immunome Appoints Phil Tsai as Chief Technical Officer

Business Wire

8 months ago

Immunome Appoints Phil Tsai as Chief Technical Officer

Argus Research

9 months ago

Daily – Vickers Top Buyers & Sellers for 05/22/2024

Insider Buying: Immunome Inc's CEO Acquires 100,000 Shares

GuruFocus.com

9 months ago

Insider Buying: Immunome Inc's CEO Acquires 100,000 Shares

MT Newswires

9 months ago

Immunome Insider Bought Shares Worth $1,388,072, According to a Recent SEC Filing

MT Newswires

9 months ago

Immunome Completes Purchase of Antibodies From Atreca

Immunome Announces Completion of Purchase of Assets from Atreca

Business Wire

9 months ago

Immunome Announces Completion of Purchase of Assets from Atreca

MT Newswires

9 months ago

Immunome Appoints Max Rosett as CFO

Immunome Announces Promotion of Max Rosett to Chief Financial Officer

Business Wire

9 months ago

Immunome Announces Promotion of Max Rosett to Chief Financial Officer

Immunome, Inc. (IMNM) Reports Q1 Loss, Misses Revenue Estimates

Zacks

9 months ago

Immunome, Inc. (IMNM) Reports Q1 Loss, Misses Revenue Estimates

Immunome Reports First Quarter 2024 Financial Results and Provides Business Update

Business Wire

9 months ago

Immunome Reports First Quarter 2024 Financial Results and Provides Business Update

Immunome to Present at 2024 Bank of America Healthcare Conference

Business Wire

9 months ago

Immunome to Present at 2024 Bank of America Healthcare Conference

Immunome Appoints Kinney Horn as Chief Business Officer

Business Wire

10 months ago

Immunome Appoints Kinney Horn as Chief Business Officer

MT Newswires

10 months ago

--JPMorgan Starts Immunome With Overweight Rating, $24 Price Target

Analysts Estimate Immunome, Inc. (IMNM) to Report a Decline in Earnings: What to Look Out for

Zacks

10 months ago

Analysts Estimate Immunome, Inc. (IMNM) to Report a Decline in Earnings: What to Look Out for

Immunome Appoints Sandra M. Swain to Board of Directors

Business Wire

10 months ago

Immunome Appoints Sandra M. Swain to Board of Directors

Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting

Business Wire

a year ago

Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting

New Strong Sell Stocks for April 4th

Zacks

a year ago

New Strong Sell Stocks for April 4th

Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets

Business Wire

a year ago

Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets

Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala

Business Wire

a year ago

Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala

Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome

GlobeNewswire

a year ago

Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome

Immunome, Inc. (NASDAQ:IMNM) surges 7.6%; individual investors who own 42% shares profited along with institutions

Simply Wall St.

a year ago

Immunome, Inc. (NASDAQ:IMNM) surges 7.6%; individual investors who own 42% shares profited along with institutions

Business Wire

a year ago

Immunome to Participate in the Leerink Partners Global Biopharma Conference

Business Wire

a year ago

Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference

Business Wire

a year ago

Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors

Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors

GlobeNewswire

a year ago

Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors

Business Wire

a year ago

Immunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Business Wire

a year ago

Immunome Announces Pricing of Public Offering of Common Stock

Business Wire

a year ago

Immunome Announces Proposed Public Offering of Common Stock

Insiders See US$1.25m Investment In Immunome Jump Last Week

Simply Wall St.

a year ago

Insiders See US$1.25m Investment In Immunome Jump Last Week

Immunome (IMNM) to Acquire Desmoid Tumor Candidate, Stock Up

Zacks

a year ago

Immunome (IMNM) to Acquire Desmoid Tumor Candidate, Stock Up

Business Wire

a year ago

Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals

Business Wire

a year ago

Immunome to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

WEBINAR INVITATION | Okeanis Eco Tankers, Corp. (NYSE: ECO) (OSLO: OET) Live Investor Webinar on Friday, February 2, 2024 at 9:00 am ET

GlobeNewswire

a year ago

WEBINAR INVITATION | Okeanis Eco Tankers, Corp. (NYSE: ECO) (OSLO: OET) Live Investor Webinar on Friday, February 2, 2024 at 9:00 am ET

SpartanNash Recognized by Newsweek as One of America's Greatest Workplaces for Diversity 2024

PR Newswire

a year ago

SpartanNash Recognized by Newsweek as One of America's Greatest Workplaces for Diversity 2024

Here's Why Bank of America Is a No-Brainer Dividend Stock

Motley Fool

a year ago

Here's Why Bank of America Is a No-Brainer Dividend Stock

Q3 Earnings Outperformers: Shake Shack (NYSE:SHAK) And The Rest Of The Modern Fast Food Stocks

StockStory

a year ago

Q3 Earnings Outperformers: Shake Shack (NYSE:SHAK) And The Rest Of The Modern Fast Food Stocks

15 Best Jewelry Insurance Companies Heading into 2024

Insider Monkey

a year ago

15 Best Jewelry Insurance Companies Heading into 2024

Associated Press Finance

a year ago

Veritex Holdings: Q4 Earnings Snapshot

Veritex Holdings, Inc. Declares Cash Dividend on Common Stock

GlobeNewswire

a year ago

Veritex Holdings, Inc. Declares Cash Dividend on Common Stock

Atrion (NASDAQ:ATRI) investors are sitting on a loss of 54% if they invested five years ago

Simply Wall St.

a year ago

Atrion (NASDAQ:ATRI) investors are sitting on a loss of 54% if they invested five years ago

Personal Care Stocks Q3 Recap: Benchmarking Herbalife (NYSE:HLF)

StockStory

a year ago

Personal Care Stocks Q3 Recap: Benchmarking Herbalife (NYSE:HLF)

Unpacking Q3 Earnings: BJ's (NASDAQ:BJRI) In The Context Of Other Sit-Down Dining Stocks

StockStory

a year ago

Unpacking Q3 Earnings: BJ's (NASDAQ:BJRI) In The Context Of Other Sit-Down Dining Stocks

11 Stocks That Will Make You Rich in 5-10 Years

Insider Monkey

a year ago

11 Stocks That Will Make You Rich in 5-10 Years

Diebold Nixdorf Sets Out to Combat Shrink in Retail with New AI-powered Offering

PR Newswire

a year ago

Diebold Nixdorf Sets Out to Combat Shrink in Retail with New AI-powered Offering

Reuters

a year ago

Exclusive-Netsmart's owners explore a sale valuing it at $5 billion -sources

3 REITs with Yields over 6%

Benzinga

a year ago

3 REITs with Yields over 6%

Billionaire Steve Cohen Aggressively Bought These 12 Stocks Recently

Insider Monkey

a year ago

Billionaire Steve Cohen Aggressively Bought These 12 Stocks Recently

ProPetro Announces Fourth Quarter 2023 Earnings Call

Business Wire

a year ago

ProPetro Announces Fourth Quarter 2023 Earnings Call

Lithium Argentina Announces 2023 Production Results for Caucharí-Olaroz

GlobeNewswire

a year ago

Lithium Argentina Announces 2023 Production Results for Caucharí-Olaroz

Veradigm Inc (MDRX) Issues Refreshed Fiscal 2023 Financial Estimates

GuruFocus.com

a year ago

Veradigm Inc (MDRX) Issues Refreshed Fiscal 2023 Financial Estimates

We're Not Very Worried About SecureWorks' (NASDAQ:SCWX) Cash Burn Rate

Simply Wall St.

a year ago

We're Not Very Worried About SecureWorks' (NASDAQ:SCWX) Cash Burn Rate

Why Fast-paced Mover Greenbrier (GBX) Is a Great Choice for Value Investors

Zacks

a year ago

Why Fast-paced Mover Greenbrier (GBX) Is a Great Choice for Value Investors

Business Wire

a year ago

Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform

Kymera Therapeutics Announces Proposed Public Offering

GlobeNewswire

a year ago

Kymera Therapeutics Announces Proposed Public Offering

Business Wire

a year ago

Immunome Appoints Phil Roberts as Chief Technical Officer

Keros Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

GlobeNewswire

a year ago

Keros Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

Business Wire

a year ago

Immunome to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Business Wire

a year ago

Immunome Appoints Carol A. Schafer to Board of Directors

These Stocks Moved the Most Today: RayzeBio, Gracell, NIO, Intel, Manchester United, FedEx, Arm, and More

Barrons.com

a year ago

These Stocks Moved the Most Today: RayzeBio, Gracell, NIO, Intel, Manchester United, FedEx, Arm, and More

Reuters

a year ago

US STOCKS-Wall Street ends higher in final stretch of 2023, rate cuts in view

AstraZeneca to Acquire Gracell in $1.2 Billion Deal to Further Cell Therapy Goals

Barrons.com

a year ago

AstraZeneca to Acquire Gracell in $1.2 Billion Deal to Further Cell Therapy Goals

AstraZeneca Bolsters Cell Therapy Pipeline With Over $1B Deal For China-Based Gracell Biotechnologies

Benzinga

a year ago

AstraZeneca Bolsters Cell Therapy Pipeline With Over $1B Deal For China-Based Gracell Biotechnologies

Business Wire

a year ago

Immunome to Acquire Antibody-Related Assets and Materials from Atreca

Share on Social Networks: